Life Science Success

Send us Fan Mail

In this episode of the Lifescience Success Podcast, host Don Davis interviews James Hackworth, who shares insights about his background in physics and his journey into the life science industry. James discusses his experiences from McKinsey up to his current role at Tris Pharma, focusing on their innovative drug development and formulation technologies. He dives into the company's advancements in ADHD medications and an exciting new pain management drugs. Additionally, the conversation highlights the importance of partnerships, technology in drug development, and future industry trends. James provides a fascinating glimpse into the complexities and future of pharmaceuticals.

00:00 Welcome and Introduction
00:08 Impressions of the Bio Conference
00:42 James' Background and Journey into Pharma
03:17 Formation and Growth of Park Therapeutics
04:20 Overview of Tris Pharma
04:41 Tris Pharma's Focus and Innovations
08:00 Challenges and Opportunities in Partnering
10:58 Future of Tris Pharma and the Industry
15:41 In-depth Look at Drugs that are progressing
19:21 Conclusion and Final Thoughts

Send us Fan Mail

In this episode of the Life Science Success Podcast, Don interviews Himanshu Gadgil  from Enzine during Bio International. Himanshu explains Enzine’s dual focus on developing biosimilars and their role as a CDMO with a game-changing platform, Enzine X. They discuss how Enzine's continuous manufacturing technology significantly cuts costs and speeds up market access for clients. Himanshu also talks about Enzine’s global presence, clientele, and their future plans for expansion in the U.S. and India. Tune in to learn about the innovative approaches Enzine is bringing to the biotech industry.   00:00 Welcome and Introduction 00:07 Overview of Enzine Biotech 00:26 Enzine's Unique Manufacturing Platform 01:08 Clientele and Market Reach 01:41 Timelines and Efficiency 02:08 Future of Continuous Manufacturing 04:22 Geographical Expansion and Workforce 05:02 Enzine's Differentiators 06:10 Conclusion and Final Thoughts  

Send us Fan Mail

Join us on the Life Science Success Podcast as we delve into the fascinating journey of Andy Mehrotra, a pharmacist turned entrepreneur, who pioneered Unipr, an AI and machine learning platform aimed at addressing inefficiencies in drug development. Learn about his transition from sales and marketing to leading an innovative company, the significance of integrating and unifying data, and how Unipr is reshaping the pharmaceutical industry. Discover how Unipr is not just a solution for the life sciences but a model for other complex industries. Listen in for insights on the future of collaborative technology and its potential to accelerate health innovations.   00:00 Introduction and Guest Welcome 00:06 Guest Background and Career Journey 01:19 Transition to Leadership 02:29 Pharmaceutical Industry Insights 06:00 Introduction to Unipr 06:08 Uniper's Technology and Solutions 08:56 Client Use Cases and Success Stories 12:37 Integration vs. Unification 17:23 Conference Goals and Future Vision 21:41 Conclusion and Final Thoughts  

Send us Fan Mail

Welcome to the Life Science Success Podcast! In this episode, host Don interviews Catherine from Jellox Biotech at Bio Interntional June of 2024. Catherine shares insights into her journey from financial engineering to the life sciences field, her experience in investment banking, and her current role in business development at Jellox Biotech. She discusses Jellox Biotech's groundbreaking 3D imaging technology for digital pathology, its benefits for early cancer diagnosis, and the company's expansion plans. Catherine also sheds light on the challenges and hopes for the future, especially regarding raising venture capital and global outreach.     00:00 Introduction and Guest Welcome 00:07 Catherine's Background and Career Journey 00:43 Introduction to Jellox Biotech 01:11 Innovations in 3D Imaging and Digital Pathology 02:22 Product Development and Market Expansion 03:56 Challenges and Goals at Bio Conference 08:06 Global Expansion Plans 09:37 Future Aspirations and Technological Impact 15:39 Conclusion and Farewell

Send us Fan Mail

In this episode of the Life Science Success podcast, we have Dr. David E. Martin, the President and CEO of TrippBio, Inc., a distinguished translational scientist with over 30 years of experience in drug development. Dr. Martin has led numerous groundbreaking projects and is here to share his insights on the future of therapeutic advancements.

 

🚀 Book a FREE Digital Marketing strategy Session 👉 https://link.cxnector.com/widget/book...

 

• Introduction of Dr. David E. Martin: Dr. David E. Martin, with over 30 years in drug development, joins Don on the "Life Science Success" podcast to discuss his career and insights into therapeutic advancements.

• Dr. Martin's Background: Dr. Martin, trained as a pharmacist during the AIDS epidemic, developed a passion for infectious diseases and clinical research, which led him into life sciences. His career is marked by his role as a translational scientist focusing on groundbreaking projects.

• Professional Achievements: He highlights his work with HIV RNA as a surrogate marker in drug development, detailing his involvement in pioneering studies that validated PCR technology in clinical trials. This work significantly contributed to how drug efficacy is evaluated, particularly concerning HIV treatments.

• Role at TrippBio: As the CEO of TrippBio, Dr. Martin discusses the company's focus on developing drugs targeting host factors rather than the pathogens themselves, reducing the likelihood of resistance. TrippBio is exploring treatments for major respiratory viruses using this novel approach.

• Vision and Challenges: Dr. Martin shares his vision for TrippBio to develop a universal treatment for major respiratory infections and discusses the challenges small biotechs face, especially in securing funding and managing innovative research within tight budgets.

Send us Fan Mail

In this episode of Life Science Success, host Don Davis PhD, MBA, a digital marketer in life sciences, interviews Sabrina Johnson, CEO, and founder of DARE Bioscience. With a passion for advancing women's healthcare, Sabrina shares her career path from biochemical engineering to founding DARE Bioscience. She discusses the inception of the company, its innovative pipeline, including non-hormonal contraceptives and treatments for female arousal disorder, and the unique challenges they faced, like funding and public awareness. Sabrina emphasizes the importance of addressing unmet needs in women’s health, the strategic decisions behind their reverse merger, and her optimistic vision for the future of women's health treatments.

 

Key Takeaways

1. Purpose-Driven Innovation: Daré Bioscience was founded to address significant gaps in women's healthcare, driven by Sabrina Johnson's commitment to making a difference in areas with unmet needs.
2. Strategic Funding: Opting for a public company model allowed Daré Bioscience to secure necessary funding for its extensive product pipeline.
3. Collaborative Development: Partnering with established companies like Bayer helps in the commercialization and broader reach of innovative products.
4. Focus on Unmet Needs: The company's approach starts with identifying specific unmet needs in women's health, ensuring their products address significant issues.
5. Leadership and Authenticity: Sabrina Johnson highlights the importance of authentic leadership, problem-solving, and not shying away from challenges to drive innovation and success in healthcare.

Send us Fan Mail

In this episode of the Life Science Success Podcast, host Don Davis interviews Christian Engstrom, CEO of Bullpen, an elite club focused on fostering collaborative success in the life sciences industry. They discuss Christian's background, his motivation for creating Bullpen, the club's mission to help entrepreneurs and investors connect and support each other, and the various success stories stemming from Bullpen's initiatives. They also delve into upcoming events at the BIO International Convention and the club's future direction. Christian emphasizes the power of authentic networking and resource sharing among life sciences professionals.

 

Key Takeaways:

1. Collaborative Environment: Bullpen Ventures fosters a collaborative environment where members can network and support each other, addressing gaps in the life sciences sector.

2. Event Organization: Bullpen organizes unique, engaging events at major conferences to facilitate networking and partnerships among life science professionals.

3. Philosophical Approach: The club operates on mutual support, humility, and leveraging each member's strengths to create a supportive and effective community.

4. Non-Profit Focus: Bullpen emphasizes non-profit collaboration and relies on sponsor partners to cover costs, ensuring that resources are directed towards helping entrepreneurs and small businesses.

5. Future Vision: Bullpen aims to be a hub for DEI initiatives and a power center for collaboration, with a focus on aligning with partners who share their values and contribute to the community's success.

 

 

Send us Fan Mail

In this episode, we sit down with Aron Knickerbocker, President and CEO of Aulos Bioscience. Aron shares his extensive experience in the Life Sciences industry, highlighting his pivotal roles at RayzeBio, Five Prime Therapeutics, and Genentech. He discusses Aulos’ innovative approaches to cancer treatment, particularly in radiopharmaceuticals and targeted therapies. Aron also reflects on the key leadership advice that has shaped his career and shares his insights on the future of oncology. Tune in to learn about the groundbreaking work at Aulos and Aron’s vision for advancing cancer treatment.

 

 

• Personal Motivation: Aron’s dedication to cancer treatment is deeply personal, influenced by his mother’s death from cancer.
• Innovative Approaches: Aulos Biosciences uses immune system engagement instead of traditional radiotherapy, showing promise in early trials.
• Diverse Experience: Aron’s career spans research, business development, and leadership roles, providing a comprehensive understanding of the biotech industry.
• Leadership Values: Effective decision-making, scientific rigor, and a strong team are central to Aron’s leadership style.
• Future Vision: Aron envisions AU-007 making a significant impact on cancer treatment, with aspirations of achieving groundbreaking results in clinical trials.

https://www.lifesciencesuccess.com/pauledwards/

Send us Fan Mail

Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.

 

• Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.

• Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.

• DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.

• Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.

Send us Fan Mail

In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G.
Amado, an esteemed leader in oncology research and development, currently serving as
the President and Head of Global Oncology at Zai Lab. With a distinguished career
spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in
gene-engineered cell therapies and innovative cancer treatments.

 

• Professional Background: Dr. Rafael G. Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles.

• Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles.

• Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment.

• Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations.

• Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.